Rising Claims Denials for Cancer-Related Genetic Testing: A Call for Clarity in Coverage Standards
In a concerning trend, the rate of claim denials for cancer-related next-generation sequencing (NGS) testing has surged alongside an increase in the utilization of these advanced diagnostic tools between 2016 and 2021. This rise is notable even in light of existing coverage standards set by a Medicare national coverage determination (NCD) specifically aimed at NGS testing. A recent study, published on April 18, 2025, in JAMA Network Open, examined nearly 30,000 claims and identifies a pathology that raises questions about healthcare accessibility in a crucial area of cancer treatment.
Researchers at Georgetown University, supported by a National Cancer Institute grant, uncovered several potential reasons for the increase in denial rates. Dr. So-Yeon Kang, an assistant professor in the Department of Health Management and Policy, indicated that healthcare providers may have been slow to adapt their practices in line with the 2018 Medicare coverage decision. "We’ve seen evidence of limited responsiveness to national coverage determinations in other contexts," Dr. Kang noted, emphasizing the need for healthcare professionals to pivot alongside changing guidelines.
The findings reveal that claim denial rates increased significantly from 16.8% prior to the NCD to an alarming 27.4% post-amendment in 2020, with independent laboratories experiencing denials at nearly twice the rate compared to hospital settings. This disparity raises further questions about the equity of access to genetic testing, which may foretell the potential for individualized treatment options for cancer patients.
As people of faith, this situation resonates with the biblical principle of compassion and stewardship. Throughout his ministry, Jesus emphasized the importance of caring for the sick and marginalized. In Matthew 25:40 (NIV), He said, "Truly I tell you, whatever you did for one of the least of these brothers and sisters of mine, you did for me." The growing uncertainty surrounding coverage standards for NGS testing challenges us to reflect on how we, as a society, can better navigate the complexities of healthcare to ensure all individuals have the opportunity for equitable access to potentially lifesaving diagnostics.
The study revealed critical insights: the number of NGS testing claims increased nearly five-fold from 2016 to 2021. However, the rising costs associated with denied claims—averaging $3,800—illustrate a pressing financial burden on patients who may already be facing dire health challenges. Kang pointed out the pressing need for clarity around NGS coverage standards to alleviate unnecessary financial strain and highlight the importance of advance testing in improving cancer care outcomes.
As we consider these findings, we are reminded of our collective responsibility to advocate for fair and accessible healthcare. It calls us to reflect on how we can support systems that prioritize care that is not only effective but also equitable.
In conclusion, while the medical landscape evolves, and the promise of advanced diagnostic tools like NGS testing continues to grow, we must work towards creating an environment of compassion and support within our healthcare systems. Let us remember the words of Jeremiah 29:11 (NIV): “For I know the plans I have for you,” declares the Lord, “plans to prosper you and not to harm you, plans to give you hope and a future.” The challenge ahead invites us to engage in meaningful dialogues about healthcare ethics and justice, seeking solutions that resonate with our highest values.
Explore and dig up answers yourself with our BGodInspired Bible Tools! Be careful – each interaction is like a new treasure hunt… you can get lost for hours 🙂
